青光眼性视神经病变的管理：神经保护剂的作用。
Glaucomatous optic neuropathy management: the role of neuroprotective agents.
作者信息
L Shahsuvaryan Marianne
机构信息
Yerevan State Medical University, Yerevan, Armenia.
出版信息
Med Hypothesis Discov Innov Ophthalmol. 2013 Summer;2(2):41-6.
Abstract
Glaucoma is a major cause of worldwide irreversible blindness. The central role of raised intraocular pressure (IOP) is being questioned as many patients continue to demonstrate a clinically downhill course despite initial control of IOP. The latest concept of recognizing glaucoma as a multifactorial, progressive, neurodegenerative disease of retinal ganglion cells (RGCSs) associated with characteristic axon degeneration in the optic nerve emphasizes that several pressure-independent mechanisms are responsible for the development and progression of glaucomatous optic neuropathy. Neuroprotection as a pharmacological strategy to mitigate retinal ganglion cell death has been a popular current approach. The aim of this review is to evaluate the neuroprotective potential of calcium channel blockers in glaucomatous optic neuropathy.
摘要
青光眼是全球不可逆失明的主要原因。随着许多患者尽管眼压最初得到控制但仍继续呈现临床病情恶化的情况，眼压升高的核心作用受到质疑。将青光眼视为一种与视神经中特征性轴突退变相关的视网膜神经节细胞（RGCs）的多因素、进行性神经退行性疾病的最新概念强调，几种与压力无关的机制导致了青光眼性视神经病变的发生和发展。神经保护作为减轻视网膜神经节细胞死亡的一种药理学策略，一直是当前流行的方法。本综述的目的是评估钙通道阻滞剂在青光眼性视神经病变中的神经保护潜力。
相似文献
1
Glaucomatous optic neuropathy management: the role of neuroprotective agents.青光眼性视神经病变的管理：神经保护剂的作用。
Med Hypothesis Discov Innov Ophthalmol. 2013 Summer;2(2):41-6.
2
[The dawn of neuroprotective therapy for glaucomatous optic neuropathy].[青光眼性视神经病变神经保护治疗的曙光]
Nippon Ganka Gakkai Zasshi. 2001 Dec;105(12):866-83.
3
Neuroprotection in glaucoma: Mechanisms beyond intraocular pressure lowering.青光眼的神经保护：眼压降低以外的机制。
Mol Aspects Med. 2023 Aug;92:101193. doi: 10.1016/j.mam.2023.101193. Epub 2023 Jun 16.
4
Glaucomatous optic neuropathy: Mitochondrial dynamics, dysfunction and protection in retinal ganglion cells.青光眼性视神经病变：视网膜神经节细胞中的线粒体动力学、功能障碍及保护
Prog Retin Eye Res. 2023 Jul;95:101136. doi: 10.1016/j.preteyeres.2022.101136. Epub 2022 Nov 16.
5
[Aiming for zero blindness].追求零失明
Nippon Ganka Gakkai Zasshi. 2015 Mar;119(3):168-93; discussion 194.
6
Autophagy dysregulation and the fate of retinal ganglion cells in glaucomatous optic neuropathy.自噬失调与青光眼性视神经病变中视网膜神经节细胞的命运
Prog Brain Res. 2015;220:87-105. doi: 10.1016/bs.pbr.2015.04.009. Epub 2015 Jul 2.
7
A review of potential novel glaucoma therapeutic options independent of intraocular pressure.一篇关于独立于眼内压的潜在新型青光眼治疗选择的综述。
Surv Ophthalmol. 2022 Jul-Aug;67(4):1062-1080. doi: 10.1016/j.survophthal.2021.12.003. Epub 2021 Dec 8.
8
Gene Therapy Strategies for Glaucomatous Neurodegeneration.青光眼性神经退行性变的基因治疗策略
Curr Gene Ther. 2021;21(5):362-381. doi: 10.2174/1566523221666210126152000.
9
Neuroprotection in the treatment of glaucoma--A focus on connexin43 gap junction channel blockers.青光眼治疗中的神经保护——聚焦于连接蛋白43缝隙连接通道阻滞剂
Eur J Pharm Biopharm. 2015 Sep;95(Pt B):182-93. doi: 10.1016/j.ejpb.2015.01.031. Epub 2015 Feb 9.
10
Upregulation of the endothelin A (ET) receptor and its association with neurodegeneration in a rodent model of glaucoma.内皮素A（ET）受体上调及其与青光眼啮齿动物模型中神经退行性变的关联。
BMC Neurosci. 2017 Mar 1;18(1):27. doi: 10.1186/s12868-017-0346-3.
引用本文的文献
1
Artificial intelligence in ophthalmology.人工智能在眼科学中的应用。
Rom J Ophthalmol. 2023 Jul-Sep;67(3):207-213. doi: 10.22336/rjo.2023.37.
2
Microglial Extracellular Vesicles as Vehicles for Neurodegeneration Spreading.小胶质细胞细胞外囊泡作为神经退行性病变传播的载体。
Biomolecules. 2021 May 21;11(6):770. doi: 10.3390/biom11060770.
3
Betalain exerts a protective effect against glaucoma is majorly through the association of inflammatory cytokines.甜菜红素主要通过与炎症细胞因子的关联对青光眼发挥保护作用。
AMB Express. 2020 Jul 14;10(1):125. doi: 10.1186/s13568-020-01062-y.
4
Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.比较联合离子通道抑制剂在视神经部分横断后限制继发性退行性变的不同给药方式。
Sci Rep. 2019 Oct 25;9(1):15297. doi: 10.1038/s41598-019-51886-3.
5
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of Latanoprost.鲽源钙调蛋白-1是一种降眼压药物，也是拉坦前列素降低眼压作用所必需的下游效应分子。
Invest Ophthalmol Vis Sci. 2017 May 1;58(5):2715-2724. doi: 10.1167/iovs.16-21004.
6
The Role of Magnesium in the Pathogenesis and Treatment of Glaucoma.镁在青光眼发病机制及治疗中的作用
Int Sch Res Notices. 2014 Oct 13;2014:745439. doi: 10.1155/2014/745439. eCollection 2014.
7
Afraid of the Dark; Raising Awareness of Societies Each Year during World Glaucoma Week.怕黑；在每年的世界青光眼周提高社会认知度。
Iran J Public Health. 2015 May;44(5):716-7.
8
Neurosteroids are endogenous neuroprotectants in an ex vivo glaucoma model.在体外青光眼模型中，神经甾体是内源性神经保护剂。
Invest Ophthalmol Vis Sci. 2014 Nov 18;55(12):8531-41. doi: 10.1167/iovs.14-15624.
9
VISION 2020: The Right to Sight in 7 Years?《2020 年视觉：7 年内享有视力的权利？》
Med Hypothesis Discov Innov Ophthalmol. 2013 Summer;2(2):26-9.
本文引用的文献
1
Current primary open-angle glaucoma treatments and future directions.当前原发性开角型青光眼的治疗方法及未来发展方向。
Clin Ophthalmol. 2012;6:1699-707. doi: 10.2147/OPTH.S32933. Epub 2012 Oct 23.
2
Changes in optic nerve head circulation in response to vasoactive agents: intereye comparison in monkeys with experimental unilateral glaucoma.血管活性药物对视神经头循环的影响：实验性单侧青光眼猴双眼间比较。
Invest Ophthalmol Vis Sci. 2012 Aug 22;53(9):5771-8. doi: 10.1167/iovs.12-9765.
3
A potential neuroprotective role of apolipoprotein E-containing lipoproteins through low density lipoprotein receptor-related protein 1 in normal tension glaucoma.载脂蛋白 E 脂蛋白通过低密度脂蛋白受体相关蛋白 1 在正常眼压型青光眼的潜在神经保护作用。
J Biol Chem. 2012 Jul 20;287(30):25395-406. doi: 10.1074/jbc.M112.370130. Epub 2012 Jun 6.
4
Glaucomatous optic nerve head alterations in patients with chronic heart failure.慢性心力衰竭患者的青光眼性视神经乳头改变
Clin Ophthalmol. 2012;6:623-9. doi: 10.2147/OPTH.S30038. Epub 2012 Apr 27.
5
Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement.青光眼 2.0：神经保护、神经再生、神经增强。
Ophthalmology. 2012 May;119(5):979-86. doi: 10.1016/j.ophtha.2011.11.003. Epub 2012 Feb 18.
6
Neuroprotection in glaucoma: recent and future directions.青光眼的神经保护：近期和未来方向。
Curr Opin Ophthalmol. 2011 Mar;22(2):78-86. doi: 10.1097/ICU.0b013e32834372ec.
7
Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.青光眼的神经退行性变：进展和钙依赖性细胞内机制。
Neuroscience. 2011 Mar 10;176:1-11. doi: 10.1016/j.neuroscience.2010.12.036. Epub 2010 Dec 25.
8
Efficacy of bimatoprost 0.03% in reducing intraocular pressure in patients with 360° synechial angle-closure glaucoma: a preliminary study.贝美前列素 0.03%降低 360°房角粘连性闭角型青光眼患者眼压的疗效：初步研究。
Indian J Ophthalmol. 2011 Jan-Feb;59(1):13-6. doi: 10.4103/0301-4738.73708.
9
Use of calcium channel blockers for glaucoma.钙通道阻滞剂在青光眼治疗中的应用。
Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8.
10
Closed gateways--can neuroprotectants shield the retina in glaucoma?闭经途径——神经保护剂能保护青光眼患者的视网膜吗？
Drugs R D. 2010;10(2):93-6. doi: 10.2165/11539310-000000000-00000.
Zotero 插件